AtriCure, Inc. ATRC
Set alert
As of Nov 2, 10:55 AM ET
- YTD
- +50.95%
- 1 year
- +72.84%
- Open
- 61.70
- Prev close
- 61.25
- Mkt cap
- 3.03B
- Vol
- 313.89K
- Avg vol
- 1.01M
- EPS
- 0.21
- P/E
- 284.00
- Div yield
- 0.00%
More statistics
- Low
- 59.50
- High
- 62.33
- Forward P/E
- 141.14
- Beta
- 1.25
- Short ratio
- 3.46
- Inst. own
- 105.61%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 55.31
- 200-d avg
- 37.97
- 1y target
- 57.56
News
5 days ago seekingalpha.com
Riverwater Small Cap Strategy Q3 2026 Portfolio Update
During the third quarter of 2026, the Small Cap strategy slightly underperformed its benchmark, the Russell 2000 Index, in a period in which small cap stocks broadly declined. Top contributors…
-
1 week ago benzinga.com
Citizens Maintains Market Outperform on AtriCure, Raises Price Target to $68
Citizens analyst Daniel Stauder maintains AtriCure (NASDAQ:ATRC) with a Market Outperform and raises the price target from $52 to $68.
2 weeks ago defenseworld.net
Rep. Gilbert Ray Cisneros, Jr. Acquires Shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:TSM)
Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE: TSM). In a filing disclosed on October 12th, the…
2 weeks ago businesswire.com
AtriCure to Announce Third Quarter 2026 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and…
-
3 weeks ago benzinga.com
BTIG Maintains Buy on AtriCure, Raises Price Target to $63
BTIG analyst Ryan Zimmerman maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $55 to $63.
1 month ago benzinga.com
Abbott To Rally Over 31%? Here Are 10 Top Analyst Forecasts For Friday
Analysts raised targets for ACN, SYNA, ATRC and MPC; cut targets for CSX, NKE, MKC and FHTX, with ATRC downgraded to Hold.
1 month ago benzinga.com
This AST SpaceMobile Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Analysts downgraded FHTX, BUSE, ASTS, ATRC and EQBK; targets fell for BUSE, ASTS and EQBK but rose for ATRC.
-
1 month ago benzinga.com
Freedom Capital Markets Downgrades AtriCure to Hold, Raises Price Target to $57
Freedom Capital Markets analyst Keith Hinton downgrades AtriCure (NASDAQ:ATRC) from Buy to Hold and raises the price target from $43 to $57.
1 month ago defenseworld.net
AtriCure (NASDAQ:ATRC) Reaches New 12-Month High – Here’s What Happened
AtriCure, Inc. (NASDAQ: ATRC - Get Free Report) shares reached a new 52-week high during trading on Wednesday. The company traded as high as $60.99 and last traded at $60.9210, with a volume of 76652…
1 month ago zacks.com
Is AtriCure (ATRC) Stock Outpacing Its Medical Peers This Year?
Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
1 month ago fool.com
AtriCure CTO Sells 3,657 Shares
The transaction was valued at $201,000. The sale represented 2% of the insider's direct equity holdings prior to the transaction.
1 month ago zacks.com
Do Options Traders Know Something About AtriCure Stock We Don't?
Investors need to pay close attention to ATRC stock based on the movements in the options market lately.
1 month ago zacks.com
AtriCure, Inc. (ATRC) Hit a 52 Week High, Can the Run Continue?
AtriCure (ATRC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
-
1 month ago benzinga.com
Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600
https://www.spglobal.com/spdji/en//documents/indexnews/announcements/20260904-1484999/1484999_shuffle5461-sept2026.pdf
2 months ago benzinga.com
Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday
U.S. stocks rose; Sirius XM jumped 5.5% after Deutsche Bank’s upgrade, while GitLab, Dell and other stocks rallied on strong results.
2 months ago benzinga.com
Salesforce To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Cantor…
-
2 months ago benzinga.com
Needham Maintains Buy on AtriCure, Raises Price Target to $64
Needham analyst Mike Matson maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $45 to $64.
-
2 months ago benzinga.com
Piper Sandler Maintains Overweight on AtriCure, Raises Price Target to $60
Piper Sandler analyst Matt O'Brien maintains AtriCure (NASDAQ:ATRC) with a Overweight and raises the price target from $50 to $60.
2 months ago zacks.com
Is AtriCure (ATRC) Outperforming Other Medical Stocks This Year?
Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
2 months ago businesswire.com
AtriCure to Participate in the 2026 Wells Fargo Health Care Conference
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and…
2 months ago benzinga.com
Analog Devices To Rally Around 81%? Here Are 10 Top Analyst Forecasts For Monday
Top analysts change outlook on top names. See all rating changes, including upgrades/downgrades, on analyst ratings page. Follow other analysts.
-
2 months ago benzinga.com
BTIG Maintains Buy on AtriCure, Raises Price Target to $55
BTIG analyst Marie Thibault maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $45 to $55.
2 months ago seekingalpha.com
AtriCure: Promising Cardiovascular Surgical Platform
AtriCure is building a broader surgical platform across appendage management, ablation, and postoperative pain care. They have AtriClip, EnCompass, and cryoSPHERE. These products give them a…
2 months ago marketbeat.com
AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth
AtriCure NASDAQ: ATRC said it is seeing continued growth across its atrial fibrillation, left atrial appendage management and postsurgical pain-management businesses, supported by new product…
2 months ago gurufocus.com
A Look at AtriCure Inc (ATRC) After 3.1% Gain -- GF Value $39.42 vs Price $42.95
On August 11, 2026, AtriCure Inc (ATRC) shares rose 3.1% to a current price of $42.95, maintaining a strong performance in the market. Over the past week, the s
2 months ago fool.com
Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors
This disposition involved 3,500 shares at $38.42 per share, totaling $134,470. The transaction reduced the director's total equity holdings by 20%, based on holdings reported in the Form 4.
2 months ago fool.com
An AtriCure Director Sold $905,000 in Stock. Here's How to Read It
Karen Prange disposed of 3,564 shares for a total transaction value of approximately $138,283 on August 5. The sale resulted in a 14% reduction in the director's total direct equity holdings in the…
3 months ago gurufocus.com
A Look at AtriCure Inc (ATRC) After 6.0% Decline -- GF Value $39.32 vs Price $37.76
On July 31, 2026, AtriCure Inc (ATRC) shares fell 6.0% today, bringing the current price to $37.76. This price is within a 52-week range of $25.36 to $43.18, re
3 months ago benzinga.com
Top 3 Health Care Stocks That May Implode This Month
RSI warning: 3 overbought health care stocks could be flashing a real warning to investors with high momentum trading preferences
-
3 months ago benzinga.com
UBS Maintains Buy on AtriCure, Lowers Price Target to $50
UBS analyst Priya Sachdeva maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers the price target from $55 to $50.
3 months ago seekingalpha.com
AtriCure, Inc. (ATRC) Q2 2026 Earnings Call Transcript
AtriCure, Inc. (ATRC) Q2 2026 Earnings Call Transcript
3 months ago zacks.com
AtriCure (ATRC) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for AtriCure (ATRC) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street…
3 months ago zacks.com
AtriCure (ATRC) Q2 Earnings and Revenues Top Estimates
AtriCure (ATRC) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to a loss of $0.02 per share a year ago.
3 months ago marketbeat.com
AtriCure Q2 Earnings Call Highlights
AtriCure NASDAQ: ATRC reported double-digit revenue growth and a return to GAAP profitability in the second quarter of 2026, with management pointing to strong demand across its pain management,…
3 months ago benzinga.com
AtriCure Reports Q2 2026 Results: Full Earnings Call Transcript
AtriCure (NASDAQ:ATRC) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you…
-
3 months ago benzinga.com
AtriCure Q2 Adj. EPS $0.18 Beats $0.00 Estimate, Sales $153.600M Beat $151.842M Estimate
AtriCure (NASDAQ:ATRC) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.00 by Infinity percent. This is a 1000 percent increase over losses of $(0.02)…
-
3 months ago benzinga.com
AtriCure Raises FY2026 Adj EPS Guidance from $0.00-$0.04 to $0.24-$0.32 vs $0.06 Est; Raises FY2026 Sales Guidance from $600.000M-$610.000M to $602.000M-$610.000M vs $604.990M Est
AtriCure (NASDAQ:ATRC) raises FY2026 Adj EPS guidance from $0.00-$0.04 to $0.24-$0.32 vs $0.06 analyst estimate. Raises FY2026 sales outlook from $600.000 million-$610.000 million to $602.000…
3 months ago benzinga.com
Earnings Scheduled For July 23, 2026
Companies Reporting Before The Bell • Altisource Portfolio (NASDAQ:ASPS) is estimated to report quarterly earnings at $0.18 per share on revenue of $42.90 million. • Dime Commercial (NYSE:DCOM) is…
-
5 months ago benzinga.com
Canaccord Genuity Maintains Buy on AtriCure, Raises Price Target to $55
Canaccord Genuity analyst William Plovanic maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $53 to $55.
6 months ago benzinga.com
AtriCure Q1 2026 Earnings Call Transcript
AtriCure Q1 2026 Earnings Call Transcript
-
6 months ago benzinga.com
AtriCure Lowers FY2026 Adj EPS Guidance from $0.09-$0.15 to $0.00-$0.04 vs $0.07 Est; Affirms FY2026 Sales Guidance of $600.000M-$610.000M vs $604.053M Est
2026 Financial GuidanceFull year 2026 revenue is projected to be approximately $600 million to $610 million, and management also projects full year 2026 Adjusted EBITDA of approximately $80 million…
-
6 months ago benzinga.com
AtriCure Q1 Adj. EPS $0.00 Beats $(0.06) Estimate, Sales $141.249M Beat $139.812M Estimate
AtriCure (NASDAQ:ATRC) reported quarterly earnings of $0.00 per share which beat the analyst consensus estimate of $(0.06) by 100 percent. This is a 100 percent increase over losses of $(0.14) per…
-
8 months ago benzinga.com
This Masimo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
This Masimo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
-
8 months ago benzinga.com
Earnings Scheduled For February 17, 2026
Earnings Scheduled For February 17, 2026
1 year ago benzinga.com
Earnings Scheduled For October 29, 2025
Earnings Scheduled For October 29, 2025
1 year ago benzinga.com
Why LendingClub Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket
Why LendingClub Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session